LINGO1 and myeloid sarcoma: The past 10 years have seen tremendous progress in both fields as evidenced by the clinical trials evaluating the anti-LINGO1 antibody opicinumab [31] or the antihistamine/anticholinergic drug clemastine [32] for efficacy in MS and optic neuritis (ON), respectively.